

Intrasense announces the CE marking of Myrian 2.13, enriched by the new version of Guerbet's prostate AI

Montpellier, France, November 20, 2024, at 5:45 PM CEST

Intrasense (FR0011179886 - ALINS), medical imaging software expert and developer of Myrian® and Liflow®, is proud to announce that the Myrian® 2.13 platform has obtained the CE marking under MDR¹, including a major new version of the prostate AI developed by Guerbet, Veolity® LungCAD AI developed by MeVis Medical Solutions AG and Icobrain™ AI developed by Icometrix.

This new version enables a greater image processing capacity, differentiative factor on the growing diagnosis solution market. It ensures a more fluid integration of Myrian® into the PACS systems and ergonomics designed to optimize clinical workflow.

Myrian® has obtained the CE marking with great success for this new 2.13 version on November 8, 2024, allowing its commercialization in Europe. The perfectly integrated AI algorithms within the Myrian® platform, known for its ease of use and its large panel of functionalities, provide healthcare professionals a simplified interpretation of medical imaging exams thanks to the high-end technologies available in their workflow.

The prostate AI update within Myrian® enables a wider integration of the platform to healthcare systems. Perfectly integrated to clinical routine, the AI algorithm assists diagnosis and therapeutic decision-making. It automatically segments the prostate gland and provides its volume, facilitating the PSA density (prostate-specific antigen) calculation and PI-RADS scoring, and highlights suspicious areas with a probability map.

This new version of Myrian® allows Intrasense to enrich its high-end clinical tools solutions, providing healthcare professionals with the most efficient tools to improve diagnosis analysis.

¹ European Union Medical Devices Regulation 2017/745

About Intrasense

A French expert in medical imaging since 2004, Intrasense develops and markets software platforms in 40 countries, facilitating and securing diagnosis, decision-making and therapeutic follow-up.

Myrian®, an advanced radiology visualization solution, provides 1,200 healthcare establishments with clinical applications to help interpret all types of images. Since 2021, Intrasense has been developing a new platform dedicated to oncology, multidisciplinary and collaborative, to optimize patient care and follow-up.

A Guerbet Group subsidiary since June 2023, Intrasense continues to enrich its solutions by integrating artificial intelligence algorithms in medical imaging. Its teams work closely with healthcare professionals to help save lives.

More information at www.intrasense.fr

Intrasense

Salomé Sylvestre
Communications Officer
Phone: +334 67 13 01 30
investisseurs@intrasense.fr

NewCap

Thomas Grojean
Financial Communication and investor relations
Phone: +331 44 71 20 40
intrasense@newcap.eu